From Name:
From Email:
To Name:
To Email:

Optional Message:

Carfilzomib prolongs survival in relapsed/refractory multiple myeloma

from The Cancer Network via Modern Medicine Network

Among patients with relapsed or refractory multiple myeloma, adding carfilzomib to lenalidomide and dexamethasone (KRd) improves overall survival (OS) compared with lenalidomide and dexamethasone (Rd) alone, especially after first relapse, according to final findings from the randomized phase III ASPIRE trial (abstract 743) presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition last month in Atlanta. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063